EXONATE LIMITED

Are you attending @Ophthalmology Futures Forums, Retina Forum on the 18th September 2024? In September we will be Barcelona for the @ Ophthalmology Futures Forums, Retina Forum, clinician-driven innovation meetings focusing on new technology, entrepreneurial ventures, market access and other aspects of commercialisation in the ophthalmic healthcare sector.  We’re also excited to announce that we will be presenting at this event. To find out more about Ophthalmology Futures Forums, Retina Forum, visit: https://lnkd.in/en8aUV7h  

We’ve been shortlisted for the Business Weekly Awards! We’re honoured to have made the shortlist along with other companies in the Cambridge cluster pioneering research across #lifescience, #tech and beyond. Read the full shortlist Business Weekly newspaper: https://rb.gy/rxea6m #BusinessWeeklyAwards

This year, Macular Week runs from Monday 24th to Sunday 30th June. Diseases involving the macular, such as diabetic eye disease, are amongst the leading causes of #visionloss in the UK. We're proud to support raising awareness for these diseases, and the critical need to develop new, effective treatments. To learn more and get involved, visit Macular Society: https://lnkd.in/e2bZwK9c #MacularWeek2024 #MacularDiseases #EyeHealth

This week we’re marking Diabetes Week, a time to raise awareness and highlight the issues that matter to people with #diabetes. Diabetes is one of the most prevalent chronic disease across the globe. Characterised by elevated blood sugar levels, it can lead to complications such as heart disease, stroke, kidney disease, nerve damage, and eye diseases like diabetic retinopathy. To learn more and get involved, visit Diabetes UK: https://lnkd.in/drjj6pp #DiabetesWeek

June is Vision Research Month! This month’s initiative by Prevent Blindness highlights the challenges in ocular disease research. Join us in raising awareness for the researchers, doctors, and advocates who come together to bring the latest advancements in eye health to the forefront. #VisionResearchMonth #EyeHealth #Ophthalmology

Congratulations to Professor Robyn Guymer AM on being named as part of The Ophthalmologist 2024 Power List! We're honoured to have Professor Guymer on our Clinical Advisory Board, supporting us in our mission to transform the lives of those suffering from #visionloss. Read more: https://rb.gy/fihklk #ophthalmology

We’re pleased to welcome Dr Rafiq Hasan to our Board as Non-Executive Director. Rafiq’s extensive knowledge of the #ophthalmology sector and treatment strategies for diabetic eye disease will help to guide our ongoing strategy as we progress towards our CLEAR-DE phase IIb #clinical trial for our lead candidate, EXN407. Read the full press release here: https://rb.gy/nweo7p

Today is the 10th annual Clinical Trials Day. Organised by ACRP - Association of Clinical Research Professionals, 20th May provides a moment for reflection, recognition, and admiration for the achievements made possible by clinical trials and the people behind them. Earlier this month, our team presented Phase 1b/2a trial results for our lead candidate EXN407, the first topical SRPK1 inhibitor for the treatment of diabetic retinopathy and macular oedema. As we progress to the CLEAR-DE Phase 2b trial, we join ACRP in this year’s campaign to celebrate and recognise the clinical research workforce and their contributions to medical advances. To learn more and get involved, visit: https://lnkd.in/ge9sx8J #ClinicalTrialsDay #CTD2024

🎉Our team had a fantastic evening at Hinxton Hall Conference Centre for the Cambridge Independent Science and Technology Awards ceremony!   We are proud to have been recognised as a finalist alongside such an impressive array of companies and we send congratulations to all the finalists and winners!   #SciTechAwards

We had a fantastic time last week in Seattle for #ARVO2024! It was great to meet experts working across all aspects of #ophthalmology. We’re grateful for the opportunity to present #clinicaltrial data on EXN407, our novel, topical therapy for diabetic #macularedema. All of our three poster presentations were very well received! Photos: ➡️CEO Catherine Beech MB,ChB,OBE ➡️COO Loïc Lhuillier with Associate Professor Hemal Mehta, one of our Australia-based investigators, with Loic’s poster, ‘A double-masked, placebo-controlled, phase 1b/2a study of EXN407 eye drops in patients with mild center involving diabetic macular edema (DME)’ ➡️CEO Catherine Beech with her poster, ‘Lost in the crowd: a digital strategy to identify/enrol patients with mild diabetic macular edema into clinical trials, an Australian perspective’ If you weren't at the event, but would like to find out more or schedule a meeting with our team, contact us: info@exonate.com